Halt Medical Announces New CPT® Code From the American Medical Association for RF Ablation of Uterine Fibroids
Halt Medical is very pleased to announce that the American Medical Association (AMA) Current Procedure Terminology (CPT) Panel has established a new CPT® code specifically for Radiofrequency (RF) Ablation of Uterine Fibroids. The new CPT code reads:
Laparoscopy, surgical, ablation of uterine fibroid(s), including intraoperative ultrasound guidance and monitoring, radiofrequency
CPT codes are used by medical practitioners; including physicians, hospitals, and other healthcare providers to report healthcare services to insurers for the purpose of reimbursement. This standardized nationwide system of identification provides a uniform language for reporting medical services.
"The existence of this unique code will simplify the process, for both providers and insurers, of submitting and processing claims on behalf of their patients," according to Russ DeLonzor, President and COO of Halt Medical, Inc. Jeffrey M. Cohen, CEO of Halt Medical added that, "Category III CPT Codes are reserved for important new and emerging technologies, such as the Acessa™ Procedure, and are intended to recognize and capture reported services and procedures. As a healthcare manufacturing company, we are incredibly pleased with this development. We look forward to working with our customers and insurers to continue improving access to this procedure for those women suffering from symptomatic uterine fibroids."
The Acessa Procedure is a minimally invasive laparoscopic procedure that delivers radiofrequency energy to destroy the fibroids. After treatment, the fibroid is re-absorbed by the surrounding tissue. Acessa allows the surgeon to treat only the fibroids, while preserving normal function of the uterus. Patients typically go home the same day with little pain, and enjoy a rapid return to normal activities. More than 300 women have been successfully treated with Acessa.
About Halt Medical, Inc.
Founded in 2004, Halt Medical is a medical device company focused on establishing a new standard of care for women with symptomatic uterine fibroids. The Company has developed and launched the Acessa System and Procedure, using radiofrequency energy to destroy uterine fibroids. The results of both U.S. and international trials have led to the clearance of the product by the FDA for use in percutaneous, laparoscopic coagulation and ablation of soft tissue, including treatment of symptomatic uterine fibroids under laparoscopic ultrasound guidance. The Acessa System also has regulatory approval to treat symptomatic uterine fibroids in the European Union, Canada, and Mexico. The Company is located in Brentwood, CA. For information about the Acessa System, please visit www.haltmedical.com. To connect with Halt Medical on Facebook visit www.facebook.com/acessasystem or on Twitter at www.twitter.com/acessasystem.